BRAF and metastatic melanoma: Response to anti-BRAF therapies in patients with metastatic melanoma bearing complex mutations or single mutation other than V600 have already been described in the literature [21–24] but only p.V600 mutations are officially recognized as response biomarkers for the use of vemurafenib and dabrafenib.